Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29711772 | 1.00 | MBTD1 (0.48) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL19510910 | 0.93 | MBTD1 (0.49) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL12334568 | 0.93 | MBTD1 (0.49) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL4628598 | 0.91 | MBTD1 (0.48) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL30921576 | 0.84 | MMP2 (0.43) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL26144977 | 0.84 | MMP2 (0.43) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL30921571 | 0.82 | MBTD1 (0.40) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL26144978 | 0.82 | MBTD1 (0.40) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL4539607 | 0.82 | SPR (0.46) | MBTD1L3MBTL3CTSLCTSKMMP2 | |
| SCHEMBL30213442 | 0.81 | MBTD1 (0.40) | MBTD1L3MBTL3CTSLCTSKMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-114634483-A | Antimitotic amides for the treatment of cancer and proliferative diseases | 弗洛斯特生物科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| CN-109071545-B | Novel pyrazolopyrimidine derivatives | 拜耳动物保健有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| EP-3107909-B1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3107909-A2 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | Frost Biologic, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| CN-106068263-A | Antimitotic amides for the treatment of cancer and proliferative diseases | 弗洛斯特生物科技有限公司 | 2016-11-02 | — | — | CN | disclosed |
| WO-2015127284-A2 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | MBTD1 3328/4885L3MBTL3 2326/4885CTSL 2372/4885 |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | MBTD1 3675/4885L3MBTL3 2709/4885CTSL 3234/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | MBTD1 3328/4885L3MBTL3 2326/4885CTSL 2372/4885 |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | MBTD1 3328/4885L3MBTL3 2326/4885CTSL 2372/4885 |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | MBTD1 3328/4885L3MBTL3 2326/4885CTSL 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.